Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent (Q34116036)

31 July 2017

1 reference

title

Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent (English)

1 reference

31 July 2017

1 reference

Jeanine M Walenga

1

1 reference

31 July 2017

Walter P Jeske

2

1 reference

31 July 2017

M Michel Samama

3

1 reference

31 July 2017

F Xavier Frapaise

4

1 reference

31 July 2017

Rodger L Bick

5

1 reference

31 July 2017

Jawed Fareed

6

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

published in

1 reference

31 July 2017

volume

11

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

397-407

1 reference

Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.3.397

Synthesis of heparin fragments: a methyl alpha-pentaoside with high affinity for antithrombin III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.3.397

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.3.397

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.3.397

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.3.397

Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human serum induced stasis thrombosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.3.397

Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.3.397

Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.3.397

Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.3.397

Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.3.397

A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.3.397

10.1517/13543784.11.3.397

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference